The Dorothy Crowfoot Hodgkin Campus will boast the co-location of in vitro pharmacology and protein sciences, structural biology, drug metabolism and pharmacokinetics, computational, synthetic, and medicinal chemistry, formulation sciences, development chemistry and API manufacture. The co-location of these scientific functions enables communication and rapid and inventive problem-solving at the interfaces of disciplines as well as accelerating the speed of iterative cycles in the drug discovery and development processes, turning the site into a fully integrated R&D center.
Evotec's campus at Milton Park already benefits from the relationships and proximity with the Diamond Light Source at Harwell, making it a center of excellence in structure-based drug design. The location also facilitates partnership opportunities in the Oxford and UK-wide academic and biotech scene.
With over 600 employees on site, Evotec's Dorothy Crowfoot Hodgkin Campus now joins Evotec's sites in Toulouse and Verona as one of three fully integrated powerhouses of capacity, capabilities and know-how in integrated R&D for the benefit of its partners.
Dr Craig Johnstone, chief operating officer of Evotec, said, "Successful, fully-integrated drug discovery and development requires know-how and expertise as well as cutting-edge technologies and capabilities. We are delighted to extend our breadth of fully-integrated R&D sites with this extension to our capabilities at our Abingdon site, which we are proud to name after the X-ray crystallography technology leader and Nobel laureate: Dorothy Crowfoot Hodgkin Campus."